Menu
MorphoSys US

Investor & Media information

You are here

  1. Home
  2. Media and investors
  3. Investor & Media information

MorphoSys is strictly committed to the principle of fair disclosure. One of the most important foundations of our corporate communication is to inform all stakeholders simultaneously and comprehensively about the situation of the Company. We pay great attention to transparent and timely communication.

Corporate media releases

Date
Title

2020

  1. 17/09/2020
    MorphoSys and Incyte to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas
  2. 17/09/2020
    MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer
  3. 18/08/2020
    National Comprehensive Cancer Network(R) Adds Monjuvi(R) (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
  4. 05/08/2020
    MorphoSys Reports Second Quarter and First Half 2020 Results
  5. 01/08/2020
    FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
  6. 01/08/2020
    MorphoSys AG: Ad hoc: FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
  7. 30/07/2020
    Invitation to MorphoSys' Second Quarter and First Half 2020 Results Conference Call on August 6, 2020
  8. 14/07/2020
    MorphoSys' Licensee Janssen Announces Approval of Tremfya (Guselkumab) by U.S. FDA for Treatment of Adults with Active Psoriatic Arthritis
  9. 02/06/2020
    MorphoSys to Present at Upcoming Virtual Investor Conferences
  10. 27/05/2020
    MorphoSys AG Reports Outcome of Annual General Meeting 2020

Pages

Order form for publications and reports

Ad-hoc releases

Date
Title

2019

  1. 16/05/2019
    MorphoSys AG: Ad hoc: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity
    No download available
  2. 19/02/2019
    Ad hoc: Simon Moroney, CEO and Co-Founder of MorphoSys, Announces His Intention to Retire
    No download available
  3. 26/01/2019
    Ad hoc: MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
    No download available

2018

  1. 07/12/2018
    Ad hoc: MorphoSys Announces that According to a Presentation Title at an Upcoming Conference, Guselkumab Demonstrates Superior Long-Term Responses to Secukinumab at Week 48 in the Treatment of Moderate to Severe Psoriasis
    No download available
  2. 19/07/2018
    Ad hoc: MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Novartis and MorphoSys Increases its Financial Guidance for 2018
    No download available
  3. 18/04/2018
    Ad hoc: MorphoSys Resolves a Capital Increase to Implement the Offering of 8,300,000 American Depositary Shares (ADS) in the United States
  4. 09/04/2018
    Ad hoc: MorphoSys Announces Launch of American Depositary Shares (ADS) Offering in the United States
  5. 22/03/2018
    Ad hoc: MorphoSys Files Registration Statement in the United States for a Proposed American Depositary Shares (ADS) Offering

2017

  1. 30/11/2017
    Ad hoc: MorphoSys Increases Financial Guidance for 2017 Following Signature of Regional License Agreement for Antibody MOR202 with I-Mab
    No download available
  2. 23/10/2017
    Ad hoc: MorphoSys Receives FDA Breakthrough Therapy Designation for Its Antibody MOR208 in Relapsed/Refractory DLBCL
    No download available

Pages

Conferences

Tuesday, November 17, 2020 - 4:30pm
Stifel 2020 Virtual HC Conference

Dr. Jean-Paul Kress presents the Company at the Stifel 2020 Virtual HC Conference on Tuesday, November 17, 2020, 4:40pm CET (3:40pm GMT; 10:40am EST).

Go to the Webcast...

DocumentFile info
20201117_MorphoSys Company Presentation1.91 MB

Archive

Date
Title
MP3

2020

  1. 11/17/2020

    Stifel 2020 Virtual HC Conference

  2. 11/12/2020

    Conference Call and Webcast: Q3/9M 2020 Financial Results

  3. 09/29/2020

    Conference Call and Webcast: MorphoSys & Incyte Tafasitamab Expert Event

  4. 08/06/2020

    Conference Call and Webcast: Q2/H1 2020 Financial Results

  5. 08/03/2020

    Joint MorphoSys and Incyte Conference Call

  6. 06/18/2020

    Webcast: JMP Securities Hematology and Oncology Forum

  7. 06/10/2020

    Webcast: Goldman Sachs 41st Annual Global Healthcare Conference

  8. 06/03/2020

    Webcast: Jefferies 2020 Healthcare Conference

  9. 05/07/2020

    Conference Call and Webcast: Q1 2020 Financial Results

  10. 03/19/2020

    Conference Call and Webcast: Year End 2019

  11. 02/26/2020

    Webcast: 9th Annual SVB Leerink Global Healthcare Conference

  12. 01/15/2020

    Webcast: 38th Annual J.P. Morgan Healthcare Conference

  13. 01/13/2020

    Joint Conference Call MorphoSys and Incyte on the Global Collaboration and License Agreement for Tafasitamab

2019

  1. 12/03/2019

    31st Annual Piper Jaffray Healthcare Conference

Pages

Company Update

Date
Venue
Download

2020

  1. 10/13/2020
    Company Update

Pictures

Technology

Ylanthia

Ylanthia technology

Slonomics

Slonomics technology

HuCAL

HuCAL antibody library

HuCAL

Scientist working with the HuCAL library

Lab shots

Antibody purification

Scientist in protein chemistry lab

Daily work

MorphoSys scientist working in laboratory

Scientist with petri dishes

MorphoSys scientist handling petri dishes

Cell culture experiment

MorphoSys scientist in cell culture lab

Miscellaneous

MorphoSys Building Planegg

View of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Building Planegg

Entrance of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Logo
MorphoSys Footage Video

Copyright notice: The photos provided for download on this website can be used free of charge in the context of editorial reporting with the indication of the photo credit "©MorphoSys AG".

 

You are leaving morphosys.com and will be transferred to the MorphoSys US website which is intended for US residents.

Do you wish to proceed?

Yes No